Copyright
©The Author(s) 2020.
World J Diabetes. Dec 15, 2020; 11(12): 572-583
Published online Dec 15, 2020. doi: 10.4239/wjd.v11.i12.572
Published online Dec 15, 2020. doi: 10.4239/wjd.v11.i12.572
Figure 3 Effects of SX-fraction or insulin on insulin receptor (y) [IR(y)] phosphorylation under high (35 mmol/L) glucose.
Following a 24-h high glucose (35 mmol/L) treatment, cells were exposed to SX-fraction (300 µg/mL) or Insulin (100 nmol/L) for 15 min and subjected to enzyme-linked immunosorbent assay for IR(y). All data are mean ± SD (standard deviation) from three independent experiments (aP < 0.05 vs control or bP < 0.05 vs glucose-treated). SXF: SX-fraction; Glc: Glucose; Ins: Insulin; IR(y): Insulin receptor (y).
- Citation: Konno S. SX-fraction: Promise for novel treatment of type 2 diabetes. World J Diabetes 2020; 11(12): 572-583
- URL: https://www.wjgnet.com/1948-9358/full/v11/i12/572.htm
- DOI: https://dx.doi.org/10.4239/wjd.v11.i12.572